| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.047 | 0.6 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |